Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

中生北控生物科技股份有限公司
BIOSINO BIO-TECHNOLOGY AND SCIENCE INCORPORATION

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 8247)

VOLUNTARY ANNOUNCEMENT
STRATEGIC COOPERATION AGREEMENT

This announcement is made voluntarily by Biosino Bio-technology and Science Incorporation (the "**Company**", together with its subsidiaries, the "**Group**") to provide the shareholders and potential investors of the Company with the latest business development of the Group.

STRATEGIC COOPERATION AGREEMENT

The board (the "**Board**") of directors (the "**Directors**") of the Company is pleased to announce that on 11 February 2026, the Company and Guangdong Xiaoshou Medical Technology Co., Ltd.*(廣東小手醫療科技有限公司)("**Xiaoshou Medical**") formally entered into a strategic cooperation agreement (the "**Strategic Cooperation Agreement**") in Beijing. Pursuant to the Strategic Cooperation Agreement, the parties will carry out multi-dimensional cooperation in the field of primary healthcare, with a view to promoting the downward extension of quality medical resources and enhancing the service capabilities of primary healthcare institutions.

Under the Strategic Cooperation Agreement, the Company and Xiaoshou Medical will explore cooperation in the following areas:

(1) Capital and Strategic Synergy

The Company intends to make a strategic investment in Xiaoshou Medical with a view to establishing a long-term and stable strategic partnership and exploring innovative development models in the primary healthcare market through capital cooperation.

(2) Business and Resource Complementarity

Leveraging the Group's product strengths and research and development capabilities in the in-vitro diagnostics ("**IVD**") field, and combining Xiaoshou Medical's nationwide primary healthcare channel network and digital platform, the parties will promote the distribution of biochemical, immunological and POCT products and comprehensive solutions directly to primary healthcare institutions.

Subject to compliance requirements and data desensitisation, the parties will also enhance collaboration in data insights, product research and development, and supply chain optimisation. A joint working group will be established to develop customised products and "smart laboratory comprehensive solutions" tailored for primary healthcare scenarios.

(3) Ecosystem and Value Co creation

The parties will integrate equipment, reagents, operations and data resources to provide one-stop laboratory service solutions to regional medical alliances and chain clinics, with a view to enhancing the overall testing capabilities and operational efficiency of primary healthcare institutions.

The cooperation will be advanced in phases, commencing with strategic pilot projects and gradually expanding to large-scale implementation, while further exploring deeper industrial and capital-level collaboration.

REASONS FOR AND BENEFITS OF THE STRATEGIC COOPERATION

The Company is a leading supplier of IVD reagents in the People's Republic of China (the "**PRC**"). The Group is principally engaged in the research and development, production, sale and distribution of IVD reagent products, and provides quality and reliable disease testing reagent products to hospitals and other healthcare institutions.

The Board considers that the strategic cooperation with Xiaoshou Medical will enable the Group to integrate its strong research and development capabilities with digital channel resources, accelerate the penetration of its products and services into primary healthcare institutions, and align with national policies promoting the strengthening of primary healthcare systems and the "Healthy China" initiative.

The Board believes that the cooperation contemplated under the Strategic Cooperation Agreement will help expand the Group's market coverage, enhance its brand influence and long-term competitiveness, and is in the interests of the Company and its shareholders as a whole.

INFORMATION ON XIAOSHOU MEDICAL

Xiaoshou Medical is a primary healthcare digital service provider established in the PRC, focusing on connecting and empowering primary healthcare institutions through technology. Through years of development, it has cooperated with tens of thousands of primary healthcare institutions across various provinces in the PRC. Xiaoshou Medical has established a nationwide channel network covering a large number of primary healthcare endpoints and has independently developed an artificial intelligence (AI) digital platform that is deeply integrated with medical institution information systems, serving as a core "connector" to enhance operational efficiency and service accessibility of primary healthcare institutions.

GENERAL

The Board wishes to emphasise that, save for the principled cooperation framework set out in the Strategic Cooperation Agreement, the Company and Xiaoshou Medical (and/or their respective affiliates) have not entered into any formal or legally binding agreement in relation to the strategic cooperation. The implementation of specific cooperation projects remains subject to further negotiation and finalisation. As at the date of this announcement, the strategic cooperation may or may not result in any specific transaction or financial commitment. The Company will make further announcement(s) in compliance with the GEM Listing Rules as and when appropriate. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

For and on behalf of the Board
Biosino Bio-Technology and Science Incorporation
Chen Peng
Chairman, President and Executive Director

Beijing, China, 11 February 2026

As at the date of this announcement, the members of the Board comprise:

Chairman, President and Executive Director
Mr. Chen Peng

Vice Chairman and Executive Director
Mr. Li Zhonghua

Executive Director
Mr. Chen Zhengyong

Non-executive Director
Ms. Kang Rui

Independent non-executive Directors
Prof. Shen Jiangang, Mr. Fan Xiaoliang and Prof. Jin Tengchuan

This announcement is made in compliance with the requirements of the GEM Listing Rules to disclose information concerning the Company. The Directors jointly and severally accept full responsibility for the accuracy of the information contained in this announcement and confirm, having made all reasonable enquiries, that to the best of their knowledge and belief: (1) the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive; and (2) there are no other matters the omission of which would make any statement in this announcement misleading.

This announcement will remain on the "Latest Listed Company Announcements" page on the website of the Stock Exchange at www.hkexnews.hk for at least 7 days from the date of its publication and on the Company's website at www.zhongsheng.com.cn.